2-甲基-2-异丙基-1,3-二氧戊环 | 4405-16-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-甲基-2-异丙基-1,3-二氧戊环
• 英文名称: 2-methyl-2-isopropyl-1,3-dioxolane
• 英文别名: 2-isopropyl-2-methyl-1,3-dioxolane；2-Isopropyl-2-methyl-[1,3]dioxolan；2-methyl-2-propan-2-yl-1,3-dioxolane
• CAS: 4405-16-7
• 化学式: C₇H₁₄O₂
• 分子量: 130.187
• InChiKey: IGZQZZODNMBJLU-UHFFFAOYSA-N

物化性质

• 沸点：
  120-135 °C
• 密度：
  0.921±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2932999099

反应信息

• 作为反应物：
  描述：

  2-甲基-2-异丙基-1,3-二氧戊环 在 二碘硅烷 作用下， 以 氘代氯仿 为溶剂， 反应 0.03h， 以100%的产率得到3-甲基-2-丁酮
  参考文献：
  名称：

  Diiodosilane. 2. A multipurpose reagent for hydrolysis and reductive iodination of ketals, acetals, ketones, and aldehydes

  摘要：

  DOI：

  10.1021/jo00296a068
• 作为产物：
  描述：

  3-碘-3-甲基丁烷-2-酮 生成 2-甲基-2-异丙基-1,3-二氧戊环
  参考文献：
  名称：

  DAUBIE, CH.;BACQUET-EINHORN, C.;LELANDAIS, D., CAN. J. CHEM., 1984, 62, N 8, 1548-1551

  摘要：

  DOI：

文献信息

• DRUG DERIVATIVES
  申请人：Craighead Mark

  公开号：US20130225594A1

  公开（公告）日：2013-08-29

  The present invention relates to derivatives of known active pharmaceutical compounds. These derivatives are differentiated from the parent active compound by virtue of being redox derivatives of the active compound. This means that one or more of the functional groups in the active compound has been converted to another group in one or more reactions which may be considered to represent a change of oxidation state. We refer to these compounds generally as redox derivatives. The derivatives of the invention may be related to the original parent active pharmaceutical compound by only a single step transformation, or may be related via several synthetic steps including one or more changes of oxidation state. In certain cases, the functional group obtained after two or more transformations may be in the same oxidation state as the parent active compound (and we include these compounds in our definition of redox derivatives). In other cases, the oxidation state of the derivative of the invention may be regarded as being different from that of the parent compound. In many cases, the compounds of the invention have inherent therapeutic activity on their own account. In some cases, this activity relative to the same target or targets of the parent compound is as good as or better than the activity which the parent compound has against the target or targets.

  本发明涉及已知活性药物化合物的衍生物。这些衍生物通过是活性化合物的氧化还原衍生物与母体活性化合物相区别。这意味着活性化合物中的一个或多个官能团已转化为另一组，在一项或多项反应中，这可以被认为代表氧化态的变化。我们通常将这些化合物称为氧化还原衍生物。发明中的衍生物可能与原始母体活性药物化合物仅通过单一步骤转换有关，或者可能通过包括一个或多个氧化态变化的几个合成步骤与之相关。在某些情况下，经过两个或更多转换后获得的官能团可能与母体活性化合物处于相同的氧化态（我们将这些化合物包括在我们的氧化还原衍生物定义中）。在其他情况下，发明的衍生物的氧化态可以被认为是与母体化合物不同的。在许多情况下，发明中的化合物本身就具有固有的治疗活性。在某些情况下，相对于母体化合物的相同靶点或靶点，这种活性与母体化合物针对该靶点或靶点的活性一样好或更好。
• INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE
  申请人：Ting Pauline C.

  公开号：US20110224137A1

  公开（公告）日：2011-09-15

  The present invention relates to novel heterocyclic compounds as diacylglycerol acyltransferase (“DGAT”) inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the invention is shown below: formula (I).

  本发明涉及作为二酰基甘油酰基转移酶（“DGAT”）抑制剂的新型杂环化合物，包括所述杂环化合物的药物组合物以及利用这些化合物治疗或预防心血管疾病、代谢紊乱、肥胖或与肥胖相关的疾病、糖尿病、血脂异常、糖尿病并发症、糖耐量受损或空腹血糖受损的用途。本发明的一种示例化合物如下所示：式（I）。
• CCR2 INHIBITORS AND METHODS OF USE THEREOF
  申请人：Basak Arindrajit

  公开号：US20100234364A1

  公开（公告）日：2010-09-16

  Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, CCR9-mediated diseases, as controls in assays for the identification of CCR2 antagonists, and as controls in assays for the identification of CCR9 antagonists.

  提供了作为CCR2或CCR9受体强效拮抗剂的化合物。动物实验表明，这些化合物对于治疗炎症非常有效，而炎症是CCR2和CCR9的典型疾病。这些化合物通常是芳基磺酰胺衍生物，在制药组合物、治疗CCR2介导疾病的方法、治疗CCR9介导疾病的方法、作为CCR2拮抗剂鉴定的检测中的对照物，以及作为CCR9拮抗剂鉴定的检测中的对照物中非常有用。
• Role of aromatic <i>vs.</i> aliphatic amine for the variation of structural, electrical and catalytic behaviors in a series of silver phosphonate extended hybrid solids
  作者：Tanmay Rom、Avijit Kumar Paul

  DOI：10.1039/d0dt02796k

  日期：——

  and coordination-free templated aliphatic amine (piperazine) are studied. The connectivity of the silver ions, diphosphonate units (hedp) and bipyridine moiety can give rise to the one-dimensional structure of 1 and two-dimensional layer structure of 2. In contrast, the silver ions and diphosphonate units are connected to form the tetrameric and pentameric silver cluster units in compound 3 and 4, respectively

  四种无机-有机杂化膦酸银化合物，[Ag（C 10 H 8 N 2）（H 4 hedp）]（1），[Ag 2（C 10 H 8 N 2）（H 3 hedp）]·2H 2 O （2），[C 4 H 12 N 2 ] [Ag 4（H 2 hedp）2 ]（3）和[C 4 H 12 N 2 ] [Ag 10（H 2 hedp）4（H 2O）2 ]·2H 2 O（4）（H 5 hedp = 1-羟基乙烷-1,1-二膦酸），是通过可变胺导向的水热策略制备的。研究了配位芳族胺（4,4'-联吡啶）和无配位模板脂肪族胺（哌嗪）的后续作用。银离子的连通性，二膦酸酯单元（HEDP）和联吡啶基部分可产生的一维结构1的和二维层结构2。相反，在化合物3和4中，银离子和二膦酸酯单元连接形成四聚和五聚银簇单元， 分别。这种簇是哌嗪模板化的二维银基层结构中基本建筑单元的罕见示例。室温介电研究表明，与胺配位结构（1和2）相比
• Novel Heterocyclic Compounds as Bromodomain Inhibitors
  申请人：Liu Shuang

  公开号：US20140179648A1

  公开（公告）日：2014-06-26

  The present disclosure relates to compounds, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy.

  本公开涉及一些化合物，这些化合物通过结合溴结构域对BET蛋白功能进行抑制，并且它们在治疗中的应用。